May 18, 2020
Moderna’s coronavirus vaccine candidate expected in Phase 3 study in July
Moderna said that after two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Moderna
May 16, 2020
Moderna’s director Dr. Moncef Slaoui to oversee the White House’s operation Warp Speed initiative
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…
May 12, 2020
Moderna nets FDA fast track designation for vaccine against coronavirus
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
May 1, 2020
Moderna, Lonza work on Moderna’s Corona Vaccine
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
April 27, 2020
Moderna asks FDA to test vaccine against coronavirus
Moderna has submitted IND to USFDA for 600 participant Phase 2 study to continue from ongoing NIH-led Phase 1 study, as planning underway for Phase 3 study expected to begin in the fall of 2020.
February 25, 2020
Moderna ships mRNA vaccine against coronavirus (mRNA-1273) for Phase 1 study
mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical…
February 10, 2020
Moderna reports progress in prophylactic vaccines modality with CMV vaccine phase 2 expected in Q3 2020
Phase 2 CMV vaccine dose-confirmation study more than sixty percent enrolled mRNA-1189 to prevent infectious mononucleosis and Epstein-Barr virus (EBV)…
February 10, 2020
Moderna has first patient enrolled in phase 1/2 study of mRNA-3704 for methylmalonic acidemia
mRNA-3704 is Moderna’s first rare disease program to enter clinical studies CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage…
October 22, 2019
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
Moderna recieved second rare disease program to receive Fast Track designation with mRNA-3927, which uses the same proprietary LNP formulation as…
September 12, 2019
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
mRNA-1944 successfully encoded for functional antibody (CHKV-24) in humans at all dose levels tested (0.1, 0.3 and 0.6 mg/kg) Antibody…